Chitraporn KarnasutaRobert M. ParisJosephine H. CoxSorachai NitayaphanPunnee PitisuttithumPrasert ThongcharoenArthur E. BrownSanjay GurunathanJames TartagliaWilliam L. HeywardJohn G. McNeilDeborah L. BirxMark S. De SouzaArmed Forces Research Institute of Medical Sciences, ThailandU.S. Military HIV Research ProgramMahidol UniversitySanofi Pasteur SAAventis PasteurVaxGen, Inc.2018-06-212018-06-212005-03-31Vaccine. Vol.23, No.19 (2005), 2522-25290264410X2-s2.0-20044364751https://repository.li.mahidol.ac.th/handle/20.500.14594/16367Antibody-dependent cell-mediated cytotoxicity (ADCC) was assessed in volunteers participating in an ALVAC-HIV (vCP1521)/AIDSVAX® B/E gp120 prime-boost vaccine trial in Thailand. ADCC activity was measured using chromium release from gp120 subtype B- and CRF01_AE-coated targets in 95 vaccinees and 28 placebo recipients. There was a significant difference in the magnitude of the ADCC response to both targets between vaccinees and placebo recipients. The frequency of responders to subtype B and to CRF01_AE was 96% and 84% in the vaccine group versus 11% and 7% in the placebo group. The results demonstrate that this HIV vaccine is a potent inducer of ADCC activity and may be an additional protection of this prime-boost vaccine in preventing HIV disease.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyMedicineVeterinaryArticleSCOPUS10.1016/j.vaccine.2004.10.028